Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 5/20 | 0.39 |
| ▸ | USP25 | Q9UHP3 | 8/20 | 0.37 |
| ▸ | USP28 | Q96RU2 | 7/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24350870 | 0.91 | MAP2K1 (0.44) | MAP2K1MAP2K2 | |
| SCHEMBL22045812 | 0.91 | MAP2K1 (0.49) | MAP2K1USP28MAP2K2 | |
| SCHEMBL24906181 | 0.89 | CSF1R (0.39) | MAP2K1USP25USP28DHODHMAP2K2 | |
| SCHEMBL26047259 | 0.89 | MAP2K1 (0.42) | MAP2K1USP25MAP2K2 | |
| SCHEMBL22045814 | 0.88 | MAP2K1 (0.43) | MAP2K1USP25USP28MAP2K2 | |
| SCHEMBL24906315 | 0.87 | MAP2K1 (0.47) | MAP2K1MAP2K2 | |
| SCHEMBL26047253 | 0.87 | MAP2K1 (0.47) | MAP2K1MAP2K2 | |
| SCHEMBL24906170 | 0.87 | MAP2K1 (0.47) | MAP2K1MAP2K2 | |
| SCHEMBL24906176 | 0.85 | MAP2K1 (0.40) | MAP2K1DHODHMAP2K2CSF1RKDM4E | |
| SCHEMBL24350841 | 0.84 | MEN1 (0.39) | MAP2K1USP25DHODHMAP2K2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4233834-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4233865-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230013227-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFLECTION THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230013227-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | HTR3C, NDUFA13, NDUFAF3 | MAP2K1 4087/4885USP25 2722/4885USP28 2683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.